Expanding and Accelerating Research at University of Texas Medical Branch (UTMB) Blocker Burn Unit with TriNetX
UTMB Health's Blocker Burn Center in Galveston faced challenges conducting large-scale burn research given institutional review constraints. Adopting TriNetX's de-identified data platform gave researchers access to nearly 200,000 burn-patient records, far larger than the 10,000-15,000-patient traditional burn databases, enabling faster, more longitudinally detailed analysis. Key findings included 50 different drugs implicated in causing toxic epidermal necrolysis (versus the previously assumed 1-3), and mortality-rate variability of 20-100% for 50%-body-surface burns (versus a previously assumed flat 40% rate). UTMB now has 18 active studies underway using TriNetX data.
TriNetX is a federated real-world-data network where data stays behind each health system's firewall and is queried in place, used for cohort discovery and trial-site feasibility.
This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.
Published by TriNetX on its own site — read the original case study on trinetx.com ↗
Related use cases
- 01CRO Achieves Rapid Response, Increased Acceptance Rate Via Data-Driven Clinical Trial Site ID and Outreach Approach
- 02Sanofi UK and Royal Berkshire NHS Foundation Trust Optimize Clinical Trial Recruitment with Technology-Driven Feasibility and Site Selection Process
- 03Breaking Barriers in Lupus Research: UT Southwestern Advances Recruitment Through Real-World Data and Predictive Analytics
- 04Penn State Increases Access to Data, Enhances Research Efforts by Joining TriNetX Research Network
- 05Rapid Response and Deep Dive: University of New Mexico's Clinical & Translational Science Center Simplifies Analytics and Accelerates Time to Insight with TriNetX Platform
- 06Medical College of Wisconsin Leverages the TriNetX Platform to Win Grant to Study Outcomes and Risk Factors for Sickle Cell Disease Patients with COVID-19